title: Effect on in vivo tumorigenicity of lengthy exposure of human colon cancer cells to the differentiation agent hexamethylene bisacetamide.
abstract: The heterogeneity of tumor responses to maturation agents was studied using the multi-potential, non-cloned human colon carcinoma cell line HT29. Short-term treatment (5 cell doublings) with the differentiation agent hexamethylene bisacetamide (HMBA) induced a sharp decrease in tumorigenicity in vivo and loss of a cell surface malignancy marker. However, prolonged treatment (22 cell doublings) with the agent lead to loss of the HMBA-sensitive subpopulation from the mass culture, and enrichment of a tumorigenic, HMBA-resistant subpopulation.
authors.affiliation: Gastroenterology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
authors.forename: P
authors.initials: P
authors.lastname: Schroy
authors.forename: S
authors.initials: S
authors.lastname: Winawer
authors.forename: E
authors.initials: E
authors.lastname: Friedman
mesh_terms: D000081:Acetamides / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000951:Antigens, Neoplasm / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis; D003110:Colonic Neoplasms / Q000276:immunology / Q000473:pathology*; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D014407:Tumor Cells, Cultured
chemical_list: D000081:Acetamides; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C014026:hexamethylene bisacetamide